GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novogene Co Ltd (SHSE:688315) » Definitions » EV-to-FCF

Novogene Co (SHSE:688315) EV-to-FCF : 23.39 (As of Jul. 10, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Novogene Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Novogene Co's Enterprise Value is ¥4,668 Mil. Novogene Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was ¥200 Mil. Therefore, Novogene Co's EV-to-FCF for today is 23.39.

The historical rank and industry rank for Novogene Co's EV-to-FCF or its related term are showing as below:

SHSE:688315' s EV-to-FCF Range Over the Past 10 Years
Min: 15.28   Med: 48.75   Max: 155.62
Current: 22.37

During the past 10 years, the highest EV-to-FCF of Novogene Co was 155.62. The lowest was 15.28. And the median was 48.75.

SHSE:688315's EV-to-FCF is ranked worse than
65.57% of 395 companies
in the Biotechnology industry
Industry Median: 7.51 vs SHSE:688315: 22.37

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-07-10), Novogene Co's stock price is ¥14.94. Novogene Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was ¥0.490. Therefore, Novogene Co's PE Ratio (TTM) for today is 30.49.


Novogene Co EV-to-FCF Historical Data

The historical data trend for Novogene Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novogene Co EV-to-FCF Chart

Novogene Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 85.49 110.45 37.89 17.87

Novogene Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.25 40.63 24.31 17.87 24.16

Competitive Comparison of Novogene Co's EV-to-FCF

For the Biotechnology subindustry, Novogene Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novogene Co's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novogene Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Novogene Co's EV-to-FCF falls into.


;
;

Novogene Co EV-to-FCF Calculation

Novogene Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=4667.818/199.537
=23.39

Novogene Co's current Enterprise Value is ¥4,668 Mil.
Novogene Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥200 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novogene Co  (SHSE:688315) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Novogene Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=14.94/0.490
=30.49

Novogene Co's share price for today is ¥14.94.
Novogene Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.490.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Novogene Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Novogene Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Novogene Co Business Description

Traded in Other Exchanges
N/A
Address
No. 29, Shengshengyuan Road, Room B258, Innovation Building, Huilongguan Town, Changping District, Beijing, CHN, 100015
Novogene Co Ltd is engaged in providing multi-level scientific research and technical services and solutions for life science basic research, medical and clinical application research, and independent development and innovation of genetic testing medical equipment.

Novogene Co Headlines

No Headlines